Joanne Holland
Chief Tech/Sci/R&D Officer at CONDUIT PHARMACEUTICALS INC.
Profile
Joanne Holland is the founder of Nuformix Plc, which was founded in 2008.
She held the title of Executive Director in 2021.
Currently, Dr. Holland is the Chief Scientific Officer at Conduit Pharmaceuticals, Inc. since 2024.
Previously, she worked at Nuformix Technologies Ltd.
as the Director, Chief Scientific & Technology Officer from 2008 to 2021.
Dr. Holland obtained a doctorate degree from the University of Leeds.
Joanne Holland active positions
| Companies | Position | Start |
|---|---|---|
| CONDUIT PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 2024-03-18 |
Former positions of Joanne Holland
| Companies | Position | End |
|---|---|---|
Nuformix Technologies Ltd.
 Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | 2021-05-30 |
| NUFORMIX PLC | Founder | 2021-05-30 |
Training of Joanne Holland
| University of Leeds | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NUFORMIX PLC | Health Technology |
| CONDUIT PHARMACEUTICALS INC. | Health Technology |
| Private companies | 1 |
|---|---|
Nuformix Technologies Ltd.
Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Joanne Holland
